News / Health

Pricey Hepatitis C Drug Draws Criticism

Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014. Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014.
x
Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014.
Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014.
Anita Powell

To hear scientists talk about it, it’s nothing short of a wonder drug.

The drug is sofosbuvir, called Solvadi by its manufacturer, and its effectiveness in treating hepatitis C is so pronounced that the U.S. regulators designated it “breakthrough therapy” when they approved it for U.S. markets last year.

The catch is that it doesn’t come cheap: a single pill costs $1,000, meaning the 12-week daily dose prescribed for most patients will cost $84,000. That has brought howls of protests from activists accusing California-based Gilead Sciences of charging extortionate prices.

The dispute highlights the continuing conundrum afflicting medical research and spiraling health care costs, not only in the United States and elsewhere. What’s an appropriate price to charge for life-changing, or life-saving, drug therapies and who determines it?

Pharmaceutical companies argue they spend billions of dollars to research, discover and test such breakthrough drugs, so the production costs account for just a fraction of the company’s overall investment.

Activists-- some of whom traveled to the International AIDS conference in Melbourne, Australia, to protest Gilead’s decisions-- say drug companies gouge customers and patients with arbitrary pricing that varies widely from place to place.

“We want Gilead to explain, number one, on what they’re basing their price, whether it’s $84,000 in Europe and the United States, or even $2,000 in another country,” said Karyn Kaplan, who directs international Hepatitis and HIV policy and advocacy for the New York-based organization, the Treatment Action Group. “We want to understand what is their price based on and why won’t they give a price that will be affordable to all who need it.”

Gregg Alton, executive vice president for corporate and medical affairs for Gilead Sciences, said the drug is priced differently around the world. In Egypt, for example, which has a high rate of hepatitis C, the drug will cost just $300 per month.

Alton also noted that the company will give generic licensing to several factories, which will push down the price in the future.

“It is a fantastic drug. It’s really changing the landscape of Hepatitis C and the ability to treat hepatitis C, from a largely untreatable disease to one we can cure with a more than 90 percent rate,” he told VOA.

A study by researchers at the University of Liverpool concluded that the Solvadi pill can be made for a few U.S. cents, and that even at $1 a pill, Gilead will make a healthy profit. 

Alton said in considering the drug’s price, one should take into account that a patient who is cured of hepatitis C is free not only from the disease, but also the financial burden of future treatments.

“So actually on a cost basis, if you just look at pure cost, it is actually less expensive than treating HIV, because HIV being chronic, if you actually put the cost of actually treating for life, it turns out to be more,” Alton said. “And, again, the other thing is that we actually hope the cost comes down, that’s the purpose of the generic licensing.”

As many as 150 million people around the world have the chronic version of this liver disease that is spread, like HIV, through blood or sexual contact, according to the World Health Organization. For that reason, many HIV patients are at higher risk for contracting hepatitis C. Symptoms tend to surface late in the disease’s path, and can lead to liver cancer.

As a whole, the hepatitis family of viruses kills about 1 million people per year, according to the WHO.

For now, Gilead is raking in profits. Earlier this week, the company announced second-quarter sales of Sovaldi at a whopping $3.5 billion. That puts this little yellow pill on track to be one of the pharmaceutical industry’s biggest all-time hits, with sales expected to reach those of cholesterol-lowering drug Lipitor.

“We are not at all against Gilead making money. They are a corporation, they are a for-profit entity. So we all recognize and agree that originator companies make investments, and that they should be appropriately rewarded,” Kaplan said. “However, what that appropriate reward is and the lack of transparency in how pharmaceutical originators, pharmaceutical companies come up with that price, is not in touch with reality.”

You May Like

Sydney Hostage-taker Failed to Manipulate Social Media

Gunman forced captives to use personal Facebook, YouTube accounts to issue his demands; online community helped flag messages, urged others not to share them More

UN Seeks $8.4 Billion to Help War-Hit Syrians

Effort aimed at helping Syrians displaced within their own country and those who've fled to neighboring ones More

Who Are the Pakistani Taliban?

It's an umbrella group of militant organizations whose objective is enforcement of Sharia in Pakistan 'whether through peace or war' More

This forum has been closed.
Comment Sorting
Comments page of 2
    Next 
by: John
July 29, 2014 11:22 AM
Sam. Your approach certainly sounds like the most sensible one. You'd have to make sure you weren't ripped off by counterfeits though. But I can't think of a general solution to the overall problem. Stricter testing procedures raise the cost of drugs, and activists whine about the cost to non-white, non-Western users, so Westerners, particularly US citizens, subsidize $300 payments in Egypt by paying $84 000 themselves. One may note that Africans refuse to recognize Western patents, so the 'charitable' pharma firms are backing MSF's testing of the new sleeping sickness drug. The cost is naturally added to our bills.


by: Julie Dinkins-Borkowski
July 28, 2014 2:04 AM
I have been trying to get activist to notice the Cf drug that is hardly a cure is going to cost patients and their families $300,000 a year. And these drug companies are causing people to lose their insurance and lose their livelihood because no one wants to hire someone with such high priced health needs. Drug company execs are making billions off the backs of poor sick people, and no one cares.


by: CaliforniaDreaming from: Ventura
July 27, 2014 8:21 PM
The uproar seems to be mostly from the PMB's who are concerned only with drug costs and payments. The health insurers are the ones who benefit since this drug is a cure for a deadly disease. They save the potential payments of liver cancer treatments, transplants, and all the late stage problems that dwarf the cost of Sovaldi. If one looks at the OVERALL picture, the drug cost is minor in comparison, though $84,000 is not a minor cost; but what is the cost of a life?


by: Jonathan from: NYC
July 27, 2014 8:10 PM
This must be the gazillioneth time that an article has been written about the price of Solvaldi! Shut up already! Insurance Co's like United Health Care are paying their Execs $10-30 Million plus and Exxon books $5-10 billion dollars per quarter and nobody says anything. Isn't Provenge just as expensive and doesn't offer a cure? All the political healthcare activist should just shut up and by the stock! I did @ $63 last October! Market forces will solve any long term problems. This is America people!


by: edwin cameron from: australia
July 27, 2014 7:12 PM
meanwhile they rake in billions of $$$ and the people that can't afford the drug suffer,has anyone thought about how contagious hep c is??commonsense dictates supply = eradication,as usual Greedy Big Pharma can't get it's snout out of the trough and the virus keeps destroying family's and peoples lives,as for that comment about Gay and drug addicts deserving the cost,well i won't dignify an answer,he is clearly a [insult redacted]!!


by: Trust Gendron
July 27, 2014 2:38 PM
@ John Rudy
Not all Hep C is contracted through immoral acts. I have Hep C and got mine from a Tattoo before the Tattoo industry became
regulated by State and Fed laws.
Here are a few more ways Baby Boomers contracted Hep C :

*Blood transfusion or blood therapy or solid organ transplant performed before 1992, when a highly sensitive test to screen blood for hepatitis C was developed.
*Kidney dialysis.
*Blood products used to treat clotting problems made before 1987.
*Health care workers who have been exposed to HCV-contaminated blood through a needle stick or splashes to the eye.
*Infants born to infected mothers.
SO IN THE FUTURE, PLEASE RESEARCH YOUR FACTS BEFORE YOU COME OFF AS IGNORANT...


by: Colin Newton from: Pennsylvania
July 27, 2014 9:59 AM
Three ways to limit the price of drugs:
1) A very expensive part of drug development is clinical trials, especially phase 3. Clinical trials could be run limiting payments to doctors and hospitals and could be designed by the FDA and the drug applicants.
2) Limit payment of executives (CEOs, CFOs, presidents etc.) to an ethically acceptable amount (why does anyone need more than $10 million a year?).
3) Restructure corporate and individual tax for health care companies.


by: abbey Lynn from: wisconsin
July 27, 2014 5:48 AM
Really? I'm a 35 year old suburban housewife with two kids and I have it. I've never made any poor decisions that lead to my Hep C. I was born with a congenital heart defect and had open heart surgery when I was two. I contracted it when I was two via a blood transfusion. Get your head out of your rear please.


by: kDavis26 from: Madison, WI, USA
July 27, 2014 2:44 AM
I can see both sides of this debate. My only thought is that it shouldn't be only about Solvaldi. There are arthritis medicines that cost $60,000 per year, year after year, possibly with the patient living 25 more years and never being cured. I have a relative with severe Alzheimer's who suffered a heart attack and is in a home that costs $12,000 per month, and doesn't have enough cognition to know she's even there.

I'm OK with putting a cap on the cost/benefit ratio for medicine - we won't pay more than X for each additional healthy month some treatment is expected to create, or something along those lines, but let's not make it specific to one medicine. If Solvaldi is too expensive, ok, but then everything with a worse cost/benefit ratio is also too expensive.


by: John Rudy from: Seattle , Washington USA
July 26, 2014 11:56 PM
Hepatitis is primarily contracted through IMMORAL sex acts and / or ILLEGAL IV drug addiction . I say let these people pay for their own consequences , not others !!!

Comments page of 2
    Next 

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Will Pakistan School Shooting Galvanize Pakistan Against Extremism?i
X
Ayesha Tanzeem
December 17, 2014 11:54 AM
The attack on a military school in Pakistan’s northwest city of Peshawar left 141 dead, including 132 children. Strong statements of condemnation poured in from across the world. The country announced three days of mourning, and the leadership, both political and military, promised retribution. VOA's Ayesha Tanzeem looks at how likely the Pakistani government is to clamp down on all extremist groups.
Video

Video Will Pakistan School Shooting Galvanize Pakistan Against Extremism?

The attack on a military school in Pakistan’s northwest city of Peshawar left 141 dead, including 132 children. Strong statements of condemnation poured in from across the world. The country announced three days of mourning, and the leadership, both political and military, promised retribution. VOA's Ayesha Tanzeem looks at how likely the Pakistani government is to clamp down on all extremist groups.
Video

Video ‘Anti-Islamization’ Marches Increase Tensions In Germany

Anti-immigrant rallies in Germany have been building in recent weeks, peaking Monday night in the city of Dresden where tens of thousands of people turned out to demonstrate against what they call the ‘Islamization’ of the West. Germany has offered asylum to more Syrian refugees than any other country, and this appears to have set off the protests. Henry Ridgwell reports from London.
Video

Video Aceh Rebuilt Decade After Tsunami, But Scars Remain

On December 26, 2004 there was an earthquake in the Indian Ocean so powerful it caused the Earth’s axis to wobble a few centimeters. Onshore on the island of Sumatra, the resulting tsunami was devastating. A decade later, VOA Correspondent Steve Herman reports from Banda Aceh, Indonesia, where although there is little remaining evidence of the physical devastation, the psychological scars among survivors remain.
Video

Video Refugees Living in Kenya Long for Peace in the Home Countries

Kenya is host to numerous refugees seeking safe haven from conflict. Immigrants from Somalia face challenges in their new lives in Kenya. Ahead of International Migrants Day (December 18) Lenny Ruvaga has more for VOA News from the Kenyan capital.
Video

Video Turkey's Authoritarianism Dismays Western Allies

The Turkish government has been defiant in the face of criticism at home and abroad for its raids targeting opposition media. The European Union on Monday expressed dismay after President Recep Tayyip Erdogan lashed out at Brussels for criticizing his government's action. Turkey's bid to be considered for EU membership has been on hold while critics accuse the NATO ally of increasingly authoritarian rule. Zlatica Hoke reports.
Video

Video US-China Year in Review: Hong Kong to Climate Change

The United States is pushing for a code of conduct to resolve territorial disputes in the South China Sea as it works to improve commercial ties with Beijing. VOA State Department correspondent Scott Stearns reports on a year of U.S. policy toward China from Hong Kong to climate change.
Video

Video Japanese Leader’s Election Win Raises Potential for Conflict with Neighbors

Japan’s Prime Minister Shinzo Abe and his allies easily won a two-thirds majority in parliament Sunday, even though the country has slipped into recession under his conservative policies. VOA’s Brian Padden reports from Seoul, that the prime minister’s victory will empower him to continue economic reforms but also pursue a nationalist agenda that will likely increase tensions with Japan’s neighbors.
Video

Video Nuba Mountain Families Hide in Caves to Escape Aerial Bombings

Despite ongoing peace talks between Sudan's government and the rebel Sudan People’s Liberation Movement-North, or SPLM-N, daily aerial attacks continue in South Kordofan province’s Nuba Mountains. Adam Bailes was there and reports for VOA that government forces are targeting civilian areas, rather than military positions, with their daily bombardments.

All About America

AppleAndroid